RARE Ultragenyx Pharmaceutical Inc. Stock Quote

RARE [NASD]

Index	-	P/E	-	EPS (ttm)	-4.40	Insider Own	1.70%	Shs Outstand	60.69M	Perf Week	-8.38%
Market Cap	8.78B	Forward P/E	-	EPS next Y	-4.12	Insider Trans	-15.95%	Shs Float	57.96M	Perf Month	-13.16%
Income	-256.40M	PEG	-	EPS next Q	-1.15	Inst Own	97.90%	Short Float	10.86%	Perf Quarter	47.14%
Sales	215.10M	P/S	40.83	EPS this Y	-79.30%	Inst Trans	0.28%	Short Ratio	11.86	Perf Half Y	60.65%
Book/sh	10.98	P/B	12.57	EPS next Y	-7.80%	ROA	-20.70%	Target Price	120.33	Perf Year	126.63%
Cash/sh	12.03	P/C	11.47	EPS next 5Y	17.20%	ROE	-39.10%	52W Range	31.99 - 179.65	Perf YTD	-0.33%
Dividend	-	P/FCF	-	EPS past 5Y	-25.90%	ROI	-65.40%	52W High	-23.20%	Beta	1.97
Dividend %	-	Quick Ratio	4.30	Sales past 5Y	-	Gross Margin	97.30%	52W Low	331.29%	ATR	8.40
Employees	740	Current Ratio	4.30	Sales Q/Q	215.90%	Oper. Margin	-	RSI (14)	46.63	Volatility	5.31% 5.79%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	42.10%	Profit Margin	-	Rel Volume	1.45	Prev Close	139.87
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Oct 27 AMC	Payout	-	Avg Volume	530.85K	Price	137.97
Recom	2.20	SMA20	-9.32%	SMA50	2.68%	SMA200	50.57%	Volume	769,494	Change	-1.36%

Dec-07-20

Downgrade

Wedbush

Outperform → Neutral

$105 → $110

Nov-24-20

Resumed

Evercore ISI

In-line

$110

Nov-12-20

Downgrade

BofA Securities

Buy → Neutral

$104 → $126

Aug-02-19

Resumed

Wedbush

Outperform

$75

Mar-27-19

Upgrade

Morgan Stanley

Equal-Weight → Overweight

$68 → $83

Feb-22-19

Resumed

Raymond James

Outperform

$80

Jan-02-19

Downgrade

Raymond James

Outperform → Mkt Perform

Nov-08-18

Upgrade

Citigroup

Sell → Neutral

Sep-10-18

Initiated

Morgan Stanley

Equal-Weight

$92

Jun-21-18

Downgrade

Credit Suisse

Outperform → Neutral

May-11-18

Upgrade

Barclays

Equal Weight → Overweight

$62 → $74

May-10-18

Initiated

Goldman

Neutral

$63

Apr-18-18

Upgrade

SunTrust

Hold → Buy

Mar-22-18

Resumed

Piper Jaffray

Overweight

$67

Feb-21-18

Reiterated

Stifel

Buy

$85 → $74

Jan-22-18

Upgrade

Evercore ISI

In-line → Outperform

Jan-18-18

Initiated

Credit Suisse

Outperform

$67

Dec-05-17

Reiterated

Barclays

Equal Weight

$60 → $62

Dec-04-17

Upgrade

Jefferies

Hold → Buy

Sep-14-17

Upgrade

Wedbush

Neutral → Outperform

$62

Jan-12-21 10:04AM	Ultragenyx (RARE) Presents Preliminary 2020 Revenues & Guidance Zacks
Jan-11-21 07:00AM	Ultragenyx Reports Preliminary 2020 Revenue and 2021 Revenue Guidance for Crysvita in Ultragenyx Territories GlobeNewswire -5.88%
Jan-08-21 09:00AM	Ultragenyx Announces Progress Across Broad Gene Therapy Portfolio and Positive Longer-Term Data from Multiple Phase 1/2 Gene Therapy Studies GlobeNewswire
Jan-05-21 08:31AM	Ultragenyx to Present at 39th Annual J.P. Morgan Virtual Healthcare Conference GlobeNewswire
Jan-04-21 09:34AM	Ultragenyx (RARE) Surges on Product Approvals, Pipeline Progress Zacks
Dec-28-20 06:42AM	We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Can Easily Afford To Drive Business Growth Simply Wall St.
Dec-18-20 11:15AM	Ultragenyx (RARE), Mereo Ink Deal for Bone Disease Candidate Zacks
Dec-17-20 05:25PM	Is RARE A Good Stock To Buy Now? Insider Monkey
04:05PM	Ultragenyx and Mereo BioPharma Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta GlobeNewswire
04:05PM	Mereo BioPharma and Ultragenyx Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta GlobeNewswire
Dec-14-20 04:15PM	Ultragenyx Pharma Earns Membership In 95-Plus Composite Rating Club Investor's Business Daily +5.71%
Dec-10-20 09:40AM	Ultragenyx (RARE) Gets Orphan Drug Tag for Wilson Disease Drug Zacks
Dec-09-20 04:05PM	Ultragenyx Announces Orphan Drug Designation for UX701 for the Treatment of Wilson Disease GlobeNewswire -6.40%
Dec-05-20 01:00PM	GeneTx and Ultragenyx Announce Presentation of Phase 1/2 Data on Investigational GTX-102 in Patients with Angelman Syndrome GlobeNewswire
Nov-24-20 08:31AM	Ultragenyx to Present at Upcoming Healthcare Conferences GlobeNewswire
Nov-09-20 08:05AM	Ultragenyx Announces Plans to Build Large-scale Gene Therapy Manufacturing Facility to Support Pipeline of Therapies for Rare Diseases GlobeNewswire
Nov-05-20 08:31AM	Ultragenyx to Present at Upcoming Investor Conferences GlobeNewswire
Nov-02-20 11:20AM	Ultragenyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Oct-30-20 10:51AM	Ultragenyx Shows Rare Strength Investor's Business Daily Video +5.79%
Oct-29-20 11:02AM	Earnings Update: Here's Why Analysts Just Lifted Their Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Price Target To US$102 Simply Wall St.
Oct-28-20 07:00PM	Ultragenyx Announces Pricing of Public Offering of Common Stock GlobeNewswire
03:03PM	Solid Biosciences (SLDB) to PostQ3 Earnings: What's in Store? Zacks
10:32AM	Ultragenyx (RARE) Loss Narrows Y/Y, Revenues Beat Estimates Zacks
07:47AM	Ultragenyx Announces Proposed Public Offering of Common Stock GlobeNewswire
04:00AM	Ultragenyx Pharmaceutical Inc (RARE) Q3 2020 Earnings Call Transcript Motley Fool
Oct-27-20 05:25PM	Ultragenyx (RARE) Reports Q3 Loss, Tops Revenue Estimates Zacks +6.78%
05:01PM	Ultragenyx Pharmaceutical Sales More Than Triple, Pares Losses Investor's Business Daily
04:59PM	Recap: Ultragenyx Pharmaceutical Q3 Earnings Benzinga
04:05PM	Ultragenyx Reports Third Quarter 2020 Financial Results and Corporate Update GlobeNewswire
Oct-26-20 04:01PM	GeneTx and Ultragenyx Announce Positive Interim Phase 1/2 Data on Investigational GTX-102 Demonstrating Improvement in Patients with Angelman Syndrome GlobeNewswire
Oct-23-20 08:00AM	Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for Duchenne Muscular Dystrophy GlobeNewswire
Oct-21-20 08:31AM	Ultragenyx to Host Conference Call for Third Quarter 2020 Financial Results and Corporate Update GlobeNewswire
Oct-08-20 11:00AM	Introducing Ultragenyx Pharmaceutical (NASDAQ:RARE), The Stock That Zoomed 126% In The Last Year Simply Wall St.
Oct-07-20 05:15PM	Dow Jones Futures: Stock Market Rally, Apple, Amazon Rebound On Trump Tweet, Elon Musk Eyes Tesla Milestone; Fastly, Etsy, Alibaba, Alexion In Buy Zones Investor's Business Daily +5.97%
Oct-02-20 03:35PM	Dow Jones Erases 433-Point Early Drop As These 5 Stocks Are Defying Trump Coronavirus Infection Sell-Off Investor's Business Daily
Sep-29-20 08:57AM	Here is What Hedge Funds Think About Ultragenyx Pharmaceutical Inc (RARE) Insider Monkey
Sep-25-20 08:05AM	Ultragenyx to Present at Jefferies Gene Therapy/Editing Summit GlobeNewswire
Sep-03-20 08:31AM	Ultragenyx to Present at Upcoming Investor Conferences GlobeNewswire
Sep-02-20 08:01AM	Ultragenyx Appoints Mardi C. Dier as Chief Financial Officer GlobeNewswire
Sep-01-20 08:31AM	Ultragenyx Expands Leadership Team and Appoints Ernie Meyer as Chief Human Resources Officer GlobeNewswire
Aug-29-20 11:32AM	Ultragenyx (RARE) Up 10.4% Since Last Earnings Report: Can It Continue? Zacks
Aug-27-20 05:10PM	Ultragenyx Pharmaceutical, IBD Stock Of The Day, Targets Ultra-Rare Diseases Investor's Business Daily
Aug-19-20 03:22PM	A Quick Analysis On Ultragenyx Pharmaceutical's (NASDAQ:RARE) CEO Salary Simply Wall St.
Aug-10-20 12:43PM	Did Hedge Funds Make The Right Call On Ultragenyx Pharmaceutical Inc (RARE) ? Insider Monkey
Aug-04-20 08:31AM	Ultragenyx to Present at Upcoming Investor Conferences GlobeNewswire
Jul-31-20 01:31PM	Ultragenyx Pharmaceutical Inc (RARE) Q2 2020 Earnings Call Transcript Motley Fool
11:22AM	Ultragenyx (RARE) Loss Narrows Y/Y & Revenues Beat Estimates Zacks
Jul-30-20 07:00PM	Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:03PM	Ultragenyx Reports Second Quarter 2020 Financial Results and Corporate Update GlobeNewswire
Jul-24-20 08:35AM	Ultragenyx to Host Conference Call for Second Quarter 2020 Financial Results and Corporate Update GlobeNewswire
Jul-22-20 08:35AM	Ultragenyx Announces U.S. Commercial Launch of Dojolvi (triheptanoin), the First FDA-Approved Therapy for the Treatment of Long-chain Fatty Acid Oxidation Disorders GlobeNewswire
Jul-02-20 08:41AM	Ultragenyx (RARE) Looks Good: Stock Adds 8.2% in Session Zacks
Jul-01-20 12:11PM	Ultragenyx's Dojolvi Gets FDA Nod to Treat Rare Disease Zacks +8.22%
07:52AM	Ultragenyx gets second FdA approval in June MarketWatch
Jun-30-20 03:01PM	Ultragenyx Announces U.S. FDA Approval of Dojolvi (UX007/triheptanoin), the First FDA-Approved Therapy for the Treatment of Long-chain Fatty Acid Oxidation Disorders GlobeNewswire +6.19%
Jun-23-20 12:20PM	Ultragenyx Pharmaceutical Inc (RARE): Hedge Funds In Wait-and-See Mode Insider Monkey
Jun-19-20 01:16PM	FDA grants a second approval to Ultragenyx drug for rare disease MarketWatch +7.92%
10:13AM	Ultragenyx Gets FDA Nod for Label Expansion of Crysvita Zacks
Jun-18-20 01:16PM	Ultragenyx and Kyowa Kirin Announce U.S. FDA Approval of Crysvita® (burosumab) for the Treatment of Tumor-Induced Osteomalacia (TIO) GlobeNewswire
Jun-11-20 10:21AM	Utragenyx Shares Soar Above 60% YTD on Pipeline Developments Zacks -6.80%
Jun-05-20 11:31AM	Why Is Ultragenyx (RARE) Up 10.7% Since Last Earnings Report? Zacks
May-28-20 08:30AM	Ultragenyx to Present at Upcoming Investor Conferences GlobeNewswire
May-21-20 08:30AM	Ultragenyx Announces Exercise of Option to Purchase Additional Stock of Arcturus Therapeutics GlobeNewswire
May-15-20 08:00AM	Ultragenyx Announces Positive Data from Confirmatory Cohort of Phase 1/2 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) GlobeNewswire +10.13%
May-13-20 04:01PM	Ultragenyx Announces Positive Longer-term Results from First Three Cohorts of Phase 1/2 Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency GlobeNewswire
May-11-20 04:02PM	Ultragenyx to Present at BofA Securities Global Health Care Conference GlobeNewswire +5.51%
09:21AM	Analyst Estimates: Here's What Brokers Think Of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) After Its First-Quarter Report Simply Wall St.
May-07-20 07:13PM	Edited Transcript of RARE earnings conference call or presentation 6-May-20 9:00pm GMT Thomson Reuters StreetEvents
04:01PM	Ultragenyx Pharmaceutical Inc (RARE) Q1 2020 Earnings Call Transcript Motley Fool
10:12AM	Ultragenyx (RARE) Q1 Earnings & Sales Fall Short of Estimates Zacks
May-06-20 06:35PM	Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates Zacks
04:01PM	Ultragenyx Reports First Quarter 2020 Financial Results and Corporate Update GlobeNewswire
11:47AM	Will Ultragenyx Pharmaceutical Continue to Surge Higher? Zacks
May-04-20 08:30AM	GeneTx and Ultragenyx Announce GTX-102 Granted Fast Track Designation by U.S. FDA for Treatment of Angelman Syndrome GlobeNewswire +10.35%
Apr-30-20 04:05PM	Ultragenyx to Host Conference Call for First Quarter 2020 Financial Results and Corporate Update GlobeNewswire -5.04%
11:12AM	Alkermes' (ALKS) Q1 Earnings Increase Y/Y, Revenues Beat Zacks
09:26AM	Is a Surprise Coming for Ultragenyx (RARE) This Earnings Season? Zacks
Apr-28-20 06:28PM	Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy 2020 Virtual Annual Meeting GlobeNewswire -7.64%
Apr-27-20 12:32PM	Ultragenyx (RARE) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Apr-01-20 09:37AM	Ultragenyx Inks Deal With Daiichi For Gene Therapy Platform While Also Extending Cash Runway SmarterAnalyst +5.58%
Mar-31-20 08:00PM	Ultragenyx Enters into Strategic Partnership with Daiichi Sankyo for Gene Therapy Manufacturing Technology GlobeNewswire
04:05PM	REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder GlobeNewswire
Mar-29-20 12:12PM	Hedge Funds Were Selling Ultragenyx Pharmaceutical Inc (RARE) Before The Coronavirus Insider Monkey
Mar-21-20 10:39AM	Have Insiders Been Buying Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares This Year? Simply Wall St.
Mar-16-20 08:30AM	GeneTx and Ultragenyx Announce First Patient Dosed in Phase 1/2 Clinical Trial of GTX-102 in Patients with Angelman Syndrome GlobeNewswire -22.01%
Mar-14-20 11:30AM	Ultragenyx (RARE) Down 31.1% Since Last Earnings Report: Can It Rebound? Zacks
Mar-09-20 05:10PM	Ultragenyx to Present at Barclays Global Healthcare Conference GlobeNewswire -9.28%
Mar-03-20 04:15PM	Ultragenyx Announces Planned Transition of Chief Financial Officer GlobeNewswire
Feb-27-20 08:00AM	Ultragenyx and Kyowa Kirin Announce FDA Acceptance and Priority Review Designation of Supplemental Biologics License Application for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO) GlobeNewswire
Feb-21-20 08:30AM	Ultragenyx to Present at SVB Leerink Global Healthcare Conference GlobeNewswire
Feb-18-20 11:20PM	Edited Transcript of RARE earnings conference call or presentation 13-Feb-20 10:00pm GMT Thomson Reuters StreetEvents
Feb-14-20 09:18AM	Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q4 Zacks
Feb-13-20 04:01PM	Ultragenyx Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Update GlobeNewswire
Feb-06-20 04:01PM	Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2019 Financial Results and Corporate Update GlobeNewswire
Feb-05-20 05:19AM	How Should Investors Feel About Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Pay? Simply Wall St.
Jan-16-20 07:22AM	The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics Benzinga
Jan-15-20 04:01PM	GeneTx and Ultragenyx Announce Investigational New Drug (IND) Application Active for GTX-102 in Patients with Angelman Syndrome GlobeNewswire
Jan-14-20 08:53AM	Ultragenyx Provides Preliminary Crysvita 2019 Revenues Zacks +6.68%
Jan-13-20 10:14AM	Ultragenyx's Gene Therapy Positive in Genetic Disorder Study Zacks +6.60%
08:10AM	Ultragenyx Reports Preliminary 2019 Revenue and Provides 2020 Crysvita Revenue Guidance GlobeNewswire

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia; and Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII. The company is also developing small-molecule pipeline comprising UX007, a synthetic triglyceride for the treatment of long chain fatty-acid oxidation disorders, which is a set of rare metabolic diseases that prevents the conversion of fat into energy; and gene therapy pipeline consisting of DTX301, an adeno-associated virus 8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase, as well as DTX401, an AAV8 gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia. In addition, the company is developing UX068, which is in preclinical development for the treatment of creatine transporter deficiency (CTD); and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Arcturus Therapeutics Holdings Inc. to develop additional nucleic acid therapies for rare diseases. Ultragenyx Pharmaceutical Inc. was founded in 2010 and is headquartered in Novato, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Huizenga Theodore Alan	SVP, Controller and PAO	Jan 07	Option Exercise	21.00	4,000	84,000	20,436	Jan 08 07:05 PM
Huizenga Theodore Alan	SVP, Controller and PAO	Jan 07	Sale	140.65	4,000	562,600	15,716	Jan 08 07:05 PM
KAKKIS EMIL D	President & CEO	Jan 04	Sale	136.90	30,000	4,107,000	2,329,741	Jan 05 06:45 PM
KAKKIS EMIL D	President & CEO	Nov 02	Sale	96.82	30,000	2,904,600	2,359,741	Nov 04 03:44 PM
Parschauer Karah Herdman	EVP and General Counsel	Oct 30	Option Exercise	54.50	9,903	539,714	33,871	Nov 02 05:05 PM
Parschauer Karah Herdman	EVP and General Counsel	Oct 30	Sale	100.12	9,903	991,488	24,061	Nov 02 05:05 PM
Parschauer Karah Herdman	EVP and General Counsel	Oct 28	Option Exercise	54.50	97	5,287	24,065	Oct 30 05:28 PM
Parschauer Karah Herdman	EVP and General Counsel	Oct 28	Sale	100.00	97	9,700	23,968	Oct 30 05:28 PM
Bedrosian Camille L	EVP and Chief Medical Officer	Oct 14	Sale	88.00	262	23,056	35,789	Oct 16 07:22 PM
Parschauer Karah Herdman	EVP and General Counsel	Oct 14	Sale	88.00	325	28,600	23,968	Oct 16 07:21 PM
Kassberg Thomas Richard	CBO & EVP	Oct 14	Sale	87.98	262	23,051	101,478	Oct 16 07:20 PM
Pinion John Richard	See Remarks	Oct 14	Sale	88.00	262	23,056	46,299	Oct 16 07:19 PM
Harris Erik	EVP & Chief Commercial Officer	Oct 14	Sale	88.00	220	19,360	23,370	Oct 16 07:20 PM
Huang Dennis Karl	EVP & Chief Tech Ops Officer	Oct 14	Sale	88.00	262	23,056	34,699	Oct 16 07:18 PM
Huizenga Theodore Alan	SVP, Controller and PAO	Oct 14	Sale	87.98	146	12,845	16,436	Oct 16 07:16 PM
Sharp Shalini	EVP, Finance	Oct 14	Sale	87.99	375	32,996	97,812	Oct 16 07:15 PM
Pinion John Richard	See Remarks	Oct 12	Sale	94.47	2,780	262,627	46,561	Oct 13 05:55 PM
Parschauer Karah Herdman	EVP and General Counsel	Oct 08	Option Exercise	54.50	10,000	545,000	34,293	Oct 13 05:53 PM
Parschauer Karah Herdman	EVP and General Counsel	Oct 08	Sale	95.00	10,000	950,000	24,293	Oct 13 05:53 PM
Parschauer Karah Herdman	EVP and General Counsel	Oct 06	Option Exercise	48.43	10,000	484,300	34,293	Oct 07 02:57 PM
Parschauer Karah Herdman	EVP and General Counsel	Oct 06	Sale	90.00	10,000	900,000	24,293	Oct 07 02:57 PM
Parschauer Karah Herdman	EVP and General Counsel	Sep 23	Option Exercise	48.43	10,000	484,300	34,293	Sep 24 04:47 PM
Parschauer Karah Herdman	EVP and General Counsel	Sep 23	Sale	85.00	10,000	850,000	24,293	Sep 24 04:47 PM
KAKKIS EMIL D	President & CEO	Sep 01	Sale	82.63	30,000	2,478,900	2,389,741	Sep 02 04:26 PM
Aliski William	Director	Aug 21	Option Exercise	58.74	5,000	293,700	62,018	Aug 25 03:56 PM
Aliski William	Director	Aug 21	Sale	86.57	5,000	432,850	57,018	Aug 25 03:56 PM
Parschauer Karah Herdman	EVP and General Counsel	Aug 17	Option Exercise	54.50	10,000	545,000	36,663	Aug 19 02:12 PM
Sharp Shalini	CFO & Executive Vice President	Aug 17	Option Exercise	61.51	11,357	698,524	105,375	Aug 19 02:11 PM
Parschauer Karah Herdman	EVP and General Counsel	Aug 17	Sale	88.43	12,370	1,093,884	24,293	Aug 19 02:12 PM
Sharp Shalini	CFO & Executive Vice President	Aug 17	Sale	88.40	14,378	1,271,073	98,187	Aug 19 02:11 PM
SIEGALL CLAY B	Director	Aug 10	Option Exercise	40.37	1,596	64,431	4,146	Aug 11 12:21 PM
SIEGALL CLAY B	Director	Aug 10	Sale	85.01	11,346	964,523	2,550	Aug 11 12:21 PM
SIEGALL CLAY B	Director	Aug 07	Option Exercise	25.89	23,404	605,844	35,704	Aug 11 12:21 PM
SIEGALL CLAY B	Director	Aug 07	Sale	85.55	23,404	2,002,212	12,300	Aug 11 12:21 PM
KAKKIS EMIL D	President & CEO	Jul 13	Sale	85.35	40,000	3,414,000	2,419,741	Jul 15 01:22 PM
Huizenga Theodore Alan	SVP, Controller and PAO	Jul 08	Option Exercise	21.00	2,000	42,000	18,582	Jul 10 05:21 PM
Huizenga Theodore Alan	SVP, Controller and PAO	Jul 08	Sale	91.00	2,638	240,058	16,582	Jul 10 05:21 PM
Fust Matthew K	Director	Jul 06	Option Exercise	21.00	6,181	129,801	19,731	Jul 08 12:30 PM
Fust Matthew K	Director	Jul 06	Sale	90.00	6,181	556,290	13,550	Jul 08 12:30 PM
Huizenga Theodore Alan	SVP, Controller and PAO	Jul 01	Option Exercise	21.00	1,500	31,500	18,720	Jul 06 02:21 PM
Fust Matthew K	Director	Jul 01	Option Exercise	21.00	5,000	105,000	18,550	Jul 06 02:21 PM
Huizenga Theodore Alan	SVP, Controller and PAO	Jul 01	Sale	81.00	2,611	211,491	17,220	Jul 06 02:21 PM
Fust Matthew K	Director	Jul 01	Sale	85.00	5,000	425,000	13,550	Jul 06 02:21 PM
Sharp Shalini	CFO & Executive Vice President	Jun 04	Option Exercise	48.43	2,564	124,175	103,772	Jun 05 04:59 PM
Sharp Shalini	CFO & Executive Vice President	Jun 04	Sale	74.01	2,564	189,762	101,208	Jun 05 04:59 PM
Sharp Shalini	CFO & Executive Vice President	Jun 03	Option Exercise	48.43	10,234	495,633	111,442	Jun 05 04:59 PM
Sharp Shalini	CFO & Executive Vice President	Jun 03	Sale	74.23	10,234	759,670	101,208	Jun 05 04:59 PM
Huizenga Theodore Alan	SVP, Controller and PAO	May 26	Sale	74.93	260	19,482	18,331	May 27 03:14 PM
Sharp Shalini	CFO & Executive Vice President	May 19	Option Exercise	60.57	7,128	431,710	104,851	May 20 07:49 PM
Sharp Shalini	CFO & Executive Vice President	May 19	Sale	73.32	7,128	522,625	100,944	May 20 07:49 PM
Sharp Shalini	CFO & Executive Vice President	May 18	Option Exercise	70.57	19,593	1,382,678	122,929	May 20 07:49 PM
Aliski William	Director	May 18	Option Exercise	40.37	7,500	302,775	55,424	May 20 07:50 PM
Aliski William	Director	May 18	Sale	74.65	7,500	559,875	47,924	May 20 07:50 PM
Sharp Shalini	CFO & Executive Vice President	May 18	Sale	73.33	21,985	1,612,260	100,944	May 20 07:49 PM
Aliski William	Director	May 18	Sale	74.02	20,000	1,480,322	70,350	Jun 03 04:26 PM
Fust Matthew K	Director	May 18	Sale	75.00	1,875	140,625	11,000	May 19 07:13 PM
Parschauer Karah Herdman	EVP and General Counsel	May 18	Sale	74.72	2,722	203,374	27,312	May 19 07:12 PM
Huizenga Theodore Alan	SVP, Controller and PAO	May 15	Option Exercise	21.00	1,500	31,500	20,219	May 19 07:15 PM
Huizenga Theodore Alan	SVP, Controller and PAO	May 15	Sale	71.00	2,461	174,731	18,719	May 19 07:15 PM
Fust Matthew K	Director	Apr 22	Sale	65.00	1,875	121,875	12,875	Apr 24 01:00 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience